The diagnosis of idiopathic pulmonary fibrosis: current and future approaches
- PMID: 27932290
- PMCID: PMC5524148
- DOI: 10.1016/S2213-2600(16)30325-3
The diagnosis of idiopathic pulmonary fibrosis: current and future approaches
Abstract
With the recent development of two effective treatments for patients with idiopathic pulmonary fibrosis, an accurate diagnosis is crucial. The traditional approach to diagnosis emphasises the importance of thorough clinical and laboratory evaluations to exclude secondary causes of disease. High-resolution CT is a critical initial diagnostic test and acts as a tool to identify patients who should undergo surgical lung biopsy to secure a definitive histological diagnosis of usual interstitial pneumonia pattern. This diagnostic approach faces several challenges. Many patients with suspected idiopathic pulmonary fibrosis present with atypical high-resolution CT characteristics but are unfit for surgical lung biopsy, therefore preventing a confident diagnosis. The state of the art suggests an iterative, multidisciplinary process that incorporates available clinical, laboratory, imaging, and histological features. Recent research has explored genomic techniques to molecularly phenotype patients with interstitial lung disease. In the future, clinicians will probably use blood-specific or lung-specific molecular markers in combination with other clinical, physiological, and imaging features to enhance diagnostic efforts, refine prognostic recommendations, and influence the initial or subsequent treatment options. There is an urgent and increasing need for well designed, large, prospective studies measuring the effect of different diagnostic approaches. Ultimately, this will help to inform the development of guidelines and tailor clinical practice for the benefit of patients.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Figures



References
-
- Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ ALAT Clinical practice guideline: treatment of idiopathic pulmonary fibrosis, an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192:e3–19. - PubMed
-
- Behr J, Bendstrup E, Crestani B, et al. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2016;4:445–53. - PubMed
-
- Jones MG, Walsh SLF, Jones KD, Richeldi L. Idiopathic pulmonary fibrosis: securing a confident diagnosis for every patient. Eur Respir J. 2016;47:1057–59. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical